QuidelOrtho (NASDAQ:QDEL) Trading Up 4.3% – What’s Next?

by · The Markets Daily

QuidelOrtho Corporation (NASDAQ:QDEL – Get Free Report)’s stock price was up 4.3% during trading on Thursday . The stock traded as high as $10.77 and last traded at $10.7860. Approximately 68,206 shares were traded during trading, a decline of 96% from the average session volume of 1,711,570 shares. The stock had previously closed at $10.34.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Wall Street Zen upgraded shares of QuidelOrtho from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. Zacks Research lowered shares of QuidelOrtho from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 12th. Jefferies Financial Group reiterated a “hold” rating on shares of QuidelOrtho in a research note on Monday, June 29th. Citigroup lifted their target price on QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Finally, JPMorgan Chase & Co. boosted their price target on QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a research note on Wednesday, July 1st. Three research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, QuidelOrtho presently has a consensus rating of “Reduce” and an average price target of $13.62.

Get Our Latest Research Report on QuidelOrtho

QuidelOrtho Stock Performance

The company has a quick ratio of 0.76, a current ratio of 1.39 and a debt-to-equity ratio of 1.43. The firm has a 50-day moving average of $14.42 and a 200 day moving average of $14.53. The stock has a market capitalization of $728.27 million, a P/E ratio of -0.69 and a beta of 0.68.

QuidelOrtho (NASDAQ:QDEL – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.18. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The firm had revenue of $630.90 million for the quarter, compared to analyst estimates of $618.72 million. During the same quarter in the previous year, the firm posted $0.12 EPS. The business’s revenue for the quarter was up 2.8% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Research analysts anticipate that QuidelOrtho Corporation will post 0.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Hantz Financial Services Inc. grew its position in QuidelOrtho by 50.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock valued at $31,000 after acquiring an additional 362 shares during the last quarter. ProShare Advisors LLC boosted its position in QuidelOrtho by 3.0% in the fourth quarter. ProShare Advisors LLC now owns 13,164 shares of the company’s stock valued at $376,000 after buying an additional 388 shares in the last quarter. Moody National Bank Trust Division increased its holdings in shares of QuidelOrtho by 1.1% during the second quarter. Moody National Bank Trust Division now owns 70,748 shares of the company’s stock worth $1,239,000 after buying an additional 789 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of QuidelOrtho by 67.7% in the 2nd quarter. GAMMA Investing LLC now owns 2,185 shares of the company’s stock valued at $38,000 after acquiring an additional 882 shares during the last quarter. Finally, Allworth Financial LP lifted its stake in shares of QuidelOrtho by 161.3% in the 2nd quarter. Allworth Financial LP now owns 3,209 shares of the company’s stock valued at $56,000 after acquiring an additional 1,981 shares during the last quarter. Institutional investors and hedge funds own 99.00% of the company’s stock.

QuidelOrtho Company Profile

(Get Free Report)

QuidelOrtho Corporation (NASDAQ:QDEL) develops, manufactures and distributes diagnostic products and solutions used to detect and monitor disease. The company serves hospitals, clinical laboratories, physician offices, retail clinics, blood banks and other healthcare providers worldwide.

Its portfolio includes point-of-care and molecular testing systems, immunoassays, clinical chemistry and immunodiagnostic platforms, and transfusion medicine products. Key product lines include the Sofia and QuickVue systems from Quidel and the VITROS, ORTHO Vision and ORTHO Workstation platforms from Ortho Clinical Diagnostics.

Read More